International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 343-350 , 1 October 2008

Improved Survival in Patients With Stage III-IV Head and Neck Cancer Treated With Radiotherapy as Primary Local Treatment Modality

  • Kyle E. Rusthoven, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Colorado Denver, Aurora, CO
    • ,
  • David Raben, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Colorado Denver, Aurora, CO
    • ,
  • Changhu Chen, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Colorado Denver, Aurora, CO
    • Corresponding Author InformationReprint requests to: Changhu Chen, M.D., Department of Radiation Oncology, University of Colorado Denver, 1665 N. Ursula St., Suite 1032, P.O. Box 6510, Mail Stop F-706, Aurora, CO 80045-0508. Tel: (720) 848-0116; Fax: (720) 848-0238

Received 10 October 2007 ,Revised 14 December 2007 ,Accepted 14 December 2007.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2007;56:106–130
  2. Gourin C, Podolsky R. Racial disparities in patients with head and neck squamous cell carcinoma. Laryngoscope. 2006;116:1093–1106
  3. Wendt TG, Grabenauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol. 1998;16:1318–1324
  4. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–1804
  5. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310–1317
  6. Adelstein DJ, Li Y, Adams GL, et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–98
  7. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol. 2000;18:1458–1464
  8. Calais G, Alfonsi M, Bardet E, et al. Randomized trail of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081–2086
  9. Cooper JS, Pajak TF, Forasteire AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–1944
  10. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–1952
  11. Pignon JP, Bourhis J, Domenge C, et al. Meta-Analysis of Chemotherapy on Head and Neck Cancer (MACH-NC) Collaborative Group Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet. 2000;355:949–955
  12. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7–16
  13. Overgaard J, Sand Hansen H, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of the head and neck: DAHANCA 6&7 randomised controlled trial. Lancet. 2003;362:933–940
  14. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet. 2006;368:843–854
  15. Hankey BF, Ries LA, Edwards BK. The Surveillance, Epidemiology and End-Results program: A national resource. Cancer Epidemiol Biomarkers Prev. 1999;8:1117–1121
  16. Harlan LC, Hankey BF. The Surveillance, Epidemiology and End-Results program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol. 2003;21:2232–2233
  17. Surveillance, Epidemiology and End-Results program web site. Information about. Available from: http://seer.cancer.gov/about/. Accessed June 15, 2007.
  18. Surveillance, Epidemiology and End-Results program web site. Access. Available from: http://seer.cancer.gov/data/access.html. Accessed June 15, 2007.
  19. Greene FL, Page DL, Flemming ID. AJCC cancer staging manual. 6th ed.. Chicago: Springer; 2002;
  20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170
  22. Cox DR. Regression models and life-tables. J R Stat Soc [B]. 1972;34:187–202
  23. The Department of Veterans Affairs Laryngeal Cancer Study Group . VA larynx trial: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685–1690
  24. Lefebvre JL, Chevalier D, Luboinski B, et al. EORTC Head and Neck Cancer Cooperative Group Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst. 1996;88:890–899
  25. SEER∗Stat, version 6.3.5. Bethesda: National Cancer Institute; 2007. Available from: http://seer.cancer.gov/seerstat. Accessed June 15, 2007.
  26. Ang KK, Harris J, Garden AS, et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation Therapy Oncology Group phase II trial 99-14. J Clin Oncol. 2005;23:3008–3015
  27. RTOG 01-29 protocol. Available from: www.rtog.org. Accessed June 15, 2007.
  28. Keane TJ, Cummings BJ, O'Sullivan B, et al. A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5-fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys. 1993;25:613–618
  29. Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radiotherapy vs. concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: A randomised comparison. Br J Cancer. 2005;93:279–286
  30. Beauvillain C, Mahé M, Bourdin S, et al. Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas. Laryngoscope. 1997;107:648–653
  31. Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998;34:224–228
  32. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098
  33. Clayman GL, Weber RS, Guillamondegui O, et al. Largyngeal preservation for advanced laryngeal and hypopharyngeal cancers. Arch Otolaryngol Head Neck Surg. 1995;121:219–223
  34. Kraus DH, Pfister DG, Harrison LB, et al. Salvage laryngectomy for unsuccessful larynx preservation therapy. Arch Otol Rhinol Laryngol. 1995;104:936–941
  35. Champion GA, Piccirillo JF. Impact of computed tomography on pretherapeutic staging in patients with laryngeal cancer: Demonstration of the Will Rogers' phenomenon. Head Neck. 2004;26:972–976
  36. Thompson IM, Canby-Hagino E, Lucia MS. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keiller. J Natl Cancer Inst. 2005;97:1236–1237
  37. George S, Primrose J, Talbot R, et al. Will Rogers revisited: Prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer. 2006;95:841–847
  38. Zeitouni AG, Yamamoto YL, Black M, et al. Functional imaging of head and neck tumors using positron emission tomography. J Otolaryngol. 1994;23:77–80
  39. Berlangieri SU, Brizel DM, Scher RL, et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck. 1994;16:340–346
  40. Greven KM, Williams DW, Keyes JW, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer. 1994;74:1355–1359
  41. Sisk EA, Soltys SG, Zhu S, et al. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck. 2002;24:841–849
  42. Ringstrom E, Peters E, Hasegawa M, et al. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res. 2002;8:3187–3192
  43. Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006;119:2620–2623

 Conflict of interest: none.

PII: S0360-3016(08)00040-0

doi: 10.1016/j.ijrobp.2007.12.046

International Journal of Radiation Oncology * Biology * Physics
Volume 72, Issue 2 , Pages 343-350 , 1 October 2008

Article Tools

* Image Usage & Resolution